An Ipsen drug developed to treat the severe itching that accompanies certain liver disorders is now FDA approved for treating this complication in patients with Alagille syndrome. It’s the second ...

Credit: Mirum Pharmaceuticals. The approval was based on data from the phase 3 MARCH-PFIC trial. The Food and Drug Administration (FDA) has approved Livmarli ® (maralixibat) for the treatment of ...

Itchy skin, or pruritus, can be a symptom of liver disease. However, not everyone with liver disease experiences itching, and the specific causes of this itching are unknown. This article looks at the ...

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...

Millions of patients worldwide suffer from a chronic itching condition with no identifiable cause -- a condition known as chronic pruritus of unknown origin (CPUO) -- that has no targeted therapies ...

Please provide your email address to receive an email when new articles are posted on . The National Kidney Foundation recently hosted a live event, as a part of its NKF Live series, to discuss uremic ...

Pruritus is a not uncommon adverse event in patients receiving any type of immunotherapy for the treatment of cancer and can significantly compromise quality of life and overall function in those most ...

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability were similar in both treatment groups. Roflumilast showed significant improvement across ...

A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study. The drug ...

First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in ...